379 related articles for article (PubMed ID: 31926332)
41. Functional defects in lysosomal enzymes in autosomal dominant polycystic kidney disease (ADPKD): abnormalities in synthesis, molecular processing, polarity, and secretion.
Hartz PA; Wilson PD
Biochem Mol Med; 1997 Feb; 60(1):8-26. PubMed ID: 9066978
[TBL] [Abstract][Full Text] [Related]
42. Expression and regulation of three lysosomal cysteine protease activities during growth of a differentiating L6 rat myoblast cell line and its nonfusing variant.
Jane DT; Dufresne MJ
Biochem Cell Biol; 1994; 72(7-8):267-74. PubMed ID: 7893465
[TBL] [Abstract][Full Text] [Related]
43. Cathepsins in digestive cancers.
Chen S; Dong H; Yang S; Guo H
Oncotarget; 2017 Jun; 8(25):41690-41700. PubMed ID: 28402938
[TBL] [Abstract][Full Text] [Related]
44. Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells.
Kern U; Wischnewski V; Biniossek ML; Schilling O; Reinheckel T
Mol Cancer; 2015 Feb; 14():39. PubMed ID: 25744631
[TBL] [Abstract][Full Text] [Related]
45. Activities of proteases in parietal thrombus of aortic aneurysm.
Gacko M; Głowiński S
Clin Chim Acta; 1998 Mar; 271(2):171-7. PubMed ID: 9565332
[TBL] [Abstract][Full Text] [Related]
46. The pathophysiology of abdominal aortic aneurysm growth: corresponding and discordant inflammatory and proteolytic processes in abdominal aortic and popliteal artery aneurysms.
Abdul-Hussien H; Hanemaaijer R; Kleemann R; Verhaaren BF; van Bockel JH; Lindeman JH
J Vasc Surg; 2010 Jun; 51(6):1479-87. PubMed ID: 20488324
[TBL] [Abstract][Full Text] [Related]
47. Cystatin C and cathepsins in cardiovascular disease.
Bengtsson E; Nilsson J; Jovinge S
Front Biosci; 2008 May; 13():5780-6. PubMed ID: 18508621
[TBL] [Abstract][Full Text] [Related]
48. Role of lysosomal cathepsins in naphthazarin- and Fas-induced apoptosis in oral squamous cell carcinoma cells.
Johansson AC; Norberg-Spaak L; Roberg K
Acta Otolaryngol; 2006 Jan; 126(1):70-81. PubMed ID: 16308258
[TBL] [Abstract][Full Text] [Related]
49. Cysteine Cathepsins and their Extracellular Roles: Shaping the Microenvironment.
Vidak E; Javoršek U; Vizovišek M; Turk B
Cells; 2019 Mar; 8(3):. PubMed ID: 30897858
[No Abstract] [Full Text] [Related]
50. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
[TBL] [Abstract][Full Text] [Related]
51. L-leucyl-L-leucine methyl ester does not release cysteine cathepsins to the cytosol but inactivates them in transiently permeabilized lysosomes.
Repnik U; Borg Distefano M; Speth MT; Ng MYW; Progida C; Hoflack B; Gruenberg J; Griffiths G
J Cell Sci; 2017 Sep; 130(18):3124-3140. PubMed ID: 28754686
[TBL] [Abstract][Full Text] [Related]
52. Cathepsins in the osteoclast.
Goto T; Yamaza T; Tanaka T
J Electron Microsc (Tokyo); 2003; 52(6):551-8. PubMed ID: 14756243
[TBL] [Abstract][Full Text] [Related]
53. Cathepsins in the extracellular space: Focusing on non-lysosomal proteolytic functions with clinical implications.
Wang H; Inoue A; Lei Y; Wu H; Hong L; Cheng XW
Cell Signal; 2023 Mar; 103():110531. PubMed ID: 36417977
[TBL] [Abstract][Full Text] [Related]
54. Cysteine cathepsins and their potential in clinical therapy and biomarker discovery.
Fonović M; Turk B
Proteomics Clin Appl; 2014 Jun; 8(5-6):416-26. PubMed ID: 24470315
[TBL] [Abstract][Full Text] [Related]
55. Lysosomal cysteine proteases: structure, function and inhibition of cathepsins.
Roberts R
Drug News Perspect; 2005 Dec; 18(10):605-14. PubMed ID: 16491162
[TBL] [Abstract][Full Text] [Related]
56. Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease.
Figueiredo JL; Aikawa M; Zheng C; Aaron J; Lax L; Libby P; de Lima Filho JL; Gruener S; Fingerle J; Haap W; Hartmann G; Aikawa E
Am J Pathol; 2015 Apr; 185(4):1156-66. PubMed ID: 25680278
[TBL] [Abstract][Full Text] [Related]
57. Effect of statins on proteolytic activity in the wall of abdominal aortic aneurysms.
Abisi S; Burnand KG; Humphries J; Waltham M; Taylor P; Smith A
Br J Surg; 2008 Mar; 95(3):333-7. PubMed ID: 17968978
[TBL] [Abstract][Full Text] [Related]
58. Study of the functional share of lysosomal cathepsins by the development of specific inhibitors.
Katunuma N; Matsui A; Kakegawa T; Murata E; Asao T; Ohba Y
Adv Enzyme Regul; 1999; 39():247-60. PubMed ID: 10470376
[TBL] [Abstract][Full Text] [Related]
59. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.
Poeckel D; Funk CD
Cardiovasc Res; 2010 May; 86(2):243-53. PubMed ID: 20093252
[TBL] [Abstract][Full Text] [Related]
60. Angiotensin II-Induced vascular remodeling and hypertension involves cathepsin L/V- MEK/ERK mediated mechanism.
Lu Y; Sun X; Peng L; Jiang W; Li W; Yuan H; Cai J
Int J Cardiol; 2020 Jan; 298():98-106. PubMed ID: 31668507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
